Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeli

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and ​Pfizer-BioNTech's update

The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside

On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Tr

Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “qui

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved

President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11

https://youtu.be/H_RititNE8U

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d

Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full deta

Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.21 per share which beat the analyst consensus

Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety da

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

FDA approves Sanofi’s Sarclisa Escena, the first subcutaneous multiple myeloma treatment administere

The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc)

Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth

Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a plan

Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3

EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany an

Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chr

Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for s

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 di

Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to d

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed

"Concierge For The Field" is an AI agent that preps sales reps for meetings with physicians

Data from the global ElevAATe phase 2 study (clinical study identifier: NCT05856331) demonstrated su

Tracey Beth Hoeg was fired as FDA drug division chief amid a broader Trump administration shake-up a

Novavax shares rise after Q1 revenue beat; partnerships, credit facility, and technical levels shape

https://www.statnews.com/2026/05/06/sanofi-asks-to-pull-diabetes-drug-teplizumab-makary-fda-voucher-

Expansion to create 50 new high-skilled jobs in AI and reinforce Sanofi's long-term commitment t

Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on man

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopte

Sanofi, Regeneron win FDA nod for Dupixent in pediatric CSU as Q1 sales beat estimates, driven by st

Guidance affirmed • In 2026, sales are expected to grow by a high single-digit percentage at CER. Bu

Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.10 per share which beat the analyst consensus

Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9%

Biogen partners with Alloy Therapeutics to advance antisense therapies using RNA-targeting technolog

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market poten

Medicare Chief Chris Klomp is optimistic for strong outcome in the search of CDC leader in midst of

A federal judge warns that RFK Jr.'s vaccine overhaul likely violates federal law. Discover the